• Je něco špatně v tomto záznamu ?

CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells

M. Štětková, K. Growková, P. Fojtík, B. Valčíková, V. Palušová, A. Verlande, R. Jorda, V. Kryštof, V. Hejret, P. Alexiou, V. Rotrekl, S. Uldrijan

. 2020 ; 11 (9) : 754. [pub] 20200915

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020119

The identification of the essential role of cyclin-dependent kinases (CDKs) in the control of cell division has prompted the development of small-molecule CDK inhibitors as anticancer drugs. For many of these compounds, the precise mechanism of action in individual tumor types remains unclear as they simultaneously target different classes of CDKs - enzymes controlling the cell cycle progression as well as CDKs involved in the regulation of transcription. CDK inhibitors are also capable of activating p53 tumor suppressor in tumor cells retaining wild-type p53 gene by modulating MDM2 levels and activity. In the current study, we link, for the first time, CDK activity to the overexpression of the MDM4 (MDMX) oncogene in cancer cells. Small-molecule drugs targeting the CDK9 kinase, dinaciclib, flavopiridol, roscovitine, AT-7519, SNS-032, and DRB, diminished MDM4 levels and activated p53 in A375 melanoma and MCF7 breast carcinoma cells with only a limited effect on MDM2. These results suggest that MDM4, rather than MDM2, could be the primary transcriptional target of pharmacological CDK inhibitors in the p53 pathway. CDK9 inhibitor atuveciclib downregulated MDM4 and enhanced p53 activity induced by nutlin-3a, an inhibitor of p53-MDM2 interaction, and synergized with nutlin-3a in killing A375 melanoma cells. Furthermore, we found that human pluripotent stem cell lines express significant levels of MDM4, which are also maintained by CDK9 activity. In summary, we show that CDK9 activity is essential for the maintenance of high levels of MDM4 in human cells, and drugs targeting CDK9 might restore p53 tumor suppressor function in malignancies overexpressing MDM4.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020119
003      
CZ-PrNML
005      
20210830101731.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41419-020-02971-3 $2 doi
035    __
$a (PubMed)32934219
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Štětková, Monika $u Faculty of Medicine, Department of Biology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
245    10
$a CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells / $c M. Štětková, K. Growková, P. Fojtík, B. Valčíková, V. Palušová, A. Verlande, R. Jorda, V. Kryštof, V. Hejret, P. Alexiou, V. Rotrekl, S. Uldrijan
520    9_
$a The identification of the essential role of cyclin-dependent kinases (CDKs) in the control of cell division has prompted the development of small-molecule CDK inhibitors as anticancer drugs. For many of these compounds, the precise mechanism of action in individual tumor types remains unclear as they simultaneously target different classes of CDKs - enzymes controlling the cell cycle progression as well as CDKs involved in the regulation of transcription. CDK inhibitors are also capable of activating p53 tumor suppressor in tumor cells retaining wild-type p53 gene by modulating MDM2 levels and activity. In the current study, we link, for the first time, CDK activity to the overexpression of the MDM4 (MDMX) oncogene in cancer cells. Small-molecule drugs targeting the CDK9 kinase, dinaciclib, flavopiridol, roscovitine, AT-7519, SNS-032, and DRB, diminished MDM4 levels and activated p53 in A375 melanoma and MCF7 breast carcinoma cells with only a limited effect on MDM2. These results suggest that MDM4, rather than MDM2, could be the primary transcriptional target of pharmacological CDK inhibitors in the p53 pathway. CDK9 inhibitor atuveciclib downregulated MDM4 and enhanced p53 activity induced by nutlin-3a, an inhibitor of p53-MDM2 interaction, and synergized with nutlin-3a in killing A375 melanoma cells. Furthermore, we found that human pluripotent stem cell lines express significant levels of MDM4, which are also maintained by CDK9 activity. In summary, we show that CDK9 activity is essential for the maintenance of high levels of MDM4 in human cells, and drugs targeting CDK9 might restore p53 tumor suppressor function in malignancies overexpressing MDM4.
650    _2
$a zvířata $7 D000818
650    _2
$a nádory prsu $x genetika $x metabolismus $x patologie $7 D001943
650    _2
$a proteiny buněčného cyklu $x biosyntéza $x genetika $x metabolismus $7 D018797
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cyklin-dependentní kinasa 9 $x antagonisté a inhibitory $x metabolismus $7 D042863
650    _2
$a synergismus léků $7 D004357
650    _2
$a lidé $7 D006801
650    _2
$a imidazoly $x farmakologie $7 D007093
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a melanom $x genetika $x metabolismus $x patologie $7 D008545
650    _2
$a myši $7 D051379
650    _2
$a piperaziny $x farmakologie $7 D010879
650    _2
$a pluripotentní kmenové buňky $x metabolismus $7 D039904
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a protoonkogenní proteiny $x biosyntéza $x genetika $x metabolismus $7 D011518
650    _2
$a protoonkogenní proteiny c-mdm2 $x biosyntéza $x genetika $x metabolismus $7 D051736
650    _2
$a roskovitin $x farmakologie $7 D000077546
650    _2
$a sulfonamidy $x farmakologie $7 D013449
650    _2
$a genetická transkripce $7 D014158
650    _2
$a transfekce $7 D014162
650    _2
$a triaziny $x farmakologie $7 D014227
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Growková, Kateřina $u Faculty of Medicine, Department of Biology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
700    1_
$a Fojtík, Petr $u Faculty of Medicine, Department of Biology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Pekařská 53, 656 91, Brno, Czech Republic
700    1_
$a Valčíková, Barbora $u Faculty of Medicine, Department of Biology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Pekařská 53, 656 91, Brno, Czech Republic
700    1_
$a Palušová, Veronika $u Faculty of Medicine, Department of Biology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Pekařská 53, 656 91, Brno, Czech Republic
700    1_
$a Verlande, Amandine $u Faculty of Medicine, Department of Biology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Pekařská 53, 656 91, Brno, Czech Republic
700    1_
$a Jorda, Radek $u Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Šlechtitelů 27, 783 71, Olomouc, Czech Republic $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Hněvotínská 5, 779 00, Olomouc, Czech Republic
700    1_
$a Kryštof, Vladimír $u Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Šlechtitelů 27, 783 71, Olomouc, Czech Republic $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Hněvotínská 5, 779 00, Olomouc, Czech Republic
700    1_
$a Hejret, Václav $u Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
700    1_
$a Alexiou, Panagiotis $u Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
700    1_
$a Rotrekl, Vladimír $u Faculty of Medicine, Department of Biology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Pekařská 53, 656 91, Brno, Czech Republic
700    1_
$a Uldrijan, Stjepan $u Faculty of Medicine, Department of Biology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. uldrijan@med.muni.cz $u International Clinical Research Center, St. Anne's University Hospital, Pekařská 53, 656 91, Brno, Czech Republic. uldrijan@med.muni.cz
773    0_
$w MED00173233 $t Cell death & disease $x 2041-4889 $g Roč. 11, č. 9 (2020), s. 754
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32934219 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101730 $b ABA008
999    __
$a ok $b bmc $g 1690830 $s 1140565
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c 9 $d 754 $e 20200915 $i 2041-4889 $m Cell death & disease $n Cell Death Dis $x MED00173233
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace